Myelodysplastic Syndrome Post Cytotoxic Therapy

Myelodysplastic Syndrome Post Cytotoxic Therapy — Trials · CancerIndex

Clinical trials

Registered studies

15 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 6
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 17%
Top sponsor: Andrew E. Place, MD
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04726241	The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study	recruiting	Phase 1 / Phase 2	960	PedAL BCU, LLCOTHER	5	Aug 25, 2026	clinicaltrials
NCT04550442	Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia	terminated	Phase 1 / Phase 2	34	M.D. Anderson Cancer CenterOTHER